Matching articles for "Pseudomonas aeruginosa"
Cefepime/Enmetazobactam (Exblifep) for Complicated Urinary Tract Infections
The Medical Letter on Drugs and Therapeutics • July 22, 2024; (Issue 1707)
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary...
The FDA has approved Exblifep (Allecra), a fixed-dose
combination of the cephalosporin cefepime and the
beta-lactamase inhibitor enmetazobactam, for IV
treatment of adults with complicated urinary tract
infections (cUTIs), including pyelonephritis, caused
by designated susceptible microorganisms (see
Spectrum of Activity). Exblifep is the first product that
contains enmetazobactam to be approved in the US.
Antibacterial Drugs for Community-Acquired Pneumonia
The Medical Letter on Drugs and Therapeutics • January 25, 2021; (Issue 1616)
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in...
Treatment of community-acquired pneumonia (CAP)
is usually empiric, with selected antibiotic regimens
directed against some of the most common causative
pathogens. Recommended empiric regimens are
listed in Table 2; recommended antibiotic dosages for
treatment of CAP are listed in Tables 3 and 4. Joint
guidelines for treatment of CAP by the American
Thoracic Society and the Infectious Diseases Society of
America (ATS/IDSA) were updated in 2019.
Lefamulin (Xenleta) for Community-Acquired Bacterial Pneumonia
The Medical Letter on Drugs and Therapeutics • September 23, 2019; (Issue 1581)
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the...
Lefamulin (Xenleta – Nabriva), a semisynthetic
pleuromutilin antibiotic, has been approved by the
FDA for IV and oral treatment of community-acquired
bacterial pneumonia (CABP) in adults. It is the first
systemic pleuromutilin antibiotic to be approved in the
US; retapamulin (Altabax), a 1% topical ointment for
treatment of impetigo, was approved in 2007.
Eravacycline (Xerava) - An IV Tetracycline for Complicated Intra-Abdominal Infections
The Medical Letter on Drugs and Therapeutics • April 22, 2019; (Issue 1570)
Eravacycline (Xerava – Tetraphase), a new synthetic
tetracycline antibiotic, has been approved by the
FDA for IV treatment of complicated intra-abdominal
infections (cIAIs) in adults. Eravacycline is...
Eravacycline (Xerava – Tetraphase), a new synthetic
tetracycline antibiotic, has been approved by the
FDA for IV treatment of complicated intra-abdominal
infections (cIAIs) in adults. Eravacycline is structurally
similar to tigecycline (Tygacil, and generics), a broad-spectrum
tetracycline approved by the FDA for IV
treatment of complicated skin and skin structure
infections, complicated intra-abdominal infections,
and community-acquired pneumonia. A higher rate
of mortality has been reported with use of tigecycline
compared to other antibacterial drugs; it should be
used only when no suitable alternative is available.
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
The Medical Letter on Drugs and Therapeutics • August 13, 2018; (Issue 1553)
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by...
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by Pseudomonas aeruginosa or
Staphylococcus aureus in patients ≥6 months old.
Otiprio was approved earlier for prophylaxis in
children with bilateral otitis media with effusion who
are undergoing tympanostomy tube placement.
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
The Medical Letter on Drugs and Therapeutics • March 26, 2018; (Issue 1543)
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs),...
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs), including
those caused by methicillin-resistant Staphylococcus
aureus (MRSA). It is the first fluoroquinolone to be
approved for treatment of MRSA.
Comparison Table: Some Systemic Fluoroquinolones (online only)
The Medical Letter on Drugs and Therapeutics • March 26, 2018; (Issue 1543)
...
View the Comparison Table: Some Systemic Fluoroquinolones (online only)
Alternatives to Fluoroquinolones
The Medical Letter on Drugs and Therapeutics • June 6, 2016; (Issue 1496)
The FDA has announced that it is requiring changes in
the labeling of systemic fluoroquinolones to warn that
the risk of serious adverse effects, including tendinitis,
peripheral neuropathy and CNS effects,...
The FDA has announced that it is requiring changes in
the labeling of systemic fluoroquinolones to warn that
the risk of serious adverse effects, including tendinitis,
peripheral neuropathy and CNS effects, generally outweighs
their benefit for the treatment of acute sinusitis,
acute exacerbations of chronic bronchitis, and uncomplicated
urinary tract infections. For these infections, the
new labels will recommend reserving fluoroquinolones
for patients with no other treatment options.
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
The Medical Letter on Drugs and Therapeutics • May 25, 2015; (Issue 1469)
The FDA has approved ceftazidime/avibactam
(Avycaz – Actavis) for IV treatment of complicated
urinary tract and intra-abdominal infections in adults
who have limited or no other treatment...
The FDA has approved ceftazidime/avibactam
(Avycaz – Actavis) for IV treatment of complicated
urinary tract and intra-abdominal infections in adults
who have limited or no other treatment options.
Ceftolozane/tazobactam (Zerbaxa – Cubist), another
cephalosporin/beta-lactamase inhibitor combination,
was approved in 2014.
Tobramycin Inhalation Solution (Bethkis) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • June 23, 2014; (Issue 1445)
The FDA has approved another solution of the
aminoglycoside antibiotic tobramycin (Bethkis –
Chiesi/Cornerstone) for oral inhalation via a nebulizer
for management of cystic fibrosis (CF) patients...
The FDA has approved another solution of the
aminoglycoside antibiotic tobramycin (Bethkis –
Chiesi/Cornerstone) for oral inhalation via a nebulizer
for management of cystic fibrosis (CF) patients with
Pseudomonas aeruginosa.
Drugs for Bacterial Infections
The Medical Letter on Drugs and Therapeutics • July 1, 2013; (Issue 131)
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Tobramycin Inhalation Powder (Tobi Podhaler) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • June 24, 2013; (Issue 1419)
Inhaled antibiotics, which can achieve high concentrations
in the lung with minimal systemic side effects, are
probably the most effective therapy available for chronic
Pseudomonas aeruginosa infection in...
Inhaled antibiotics, which can achieve high concentrations
in the lung with minimal systemic side effects, are
probably the most effective therapy available for chronic
Pseudomonas aeruginosa infection in patients with
cystic fibrosis. An orally inhaled dry powder formulation
of the aminoglycoside antibiotic tobramycin (Tobi
Podhaler – Novartis) has been approved by the FDA for
management of P. aeruginosa pulmonary infection in
cystic fibrosis patients ≥6 years old. The new formulation
is administered via a hand-held pocket-sized inhaler.
Tobramycin is also available as an inhalation solution
(Tobi) for administration via a nebulizer. An inhalation
solution of aztreonam (Cayston), administered via a nebulizer,
is also approved for this indication.
Levofloxacin Revisited
The Medical Letter on Drugs and Therapeutics • July 11, 2011; (Issue 1368)
A Medical Letter reader has asked us to review the
safety of the fluoroquinolone antibiotic levofloxacin
(Levaquin – Ortho-McNeil-Janssen), which has just
been approved for generic use by the FDA and...
A Medical Letter reader has asked us to review the
safety of the fluoroquinolone antibiotic levofloxacin
(Levaquin – Ortho-McNeil-Janssen), which has just
been approved for generic use by the FDA and has
been at the center of some recent lawsuits regarding
the adequacy of its safety warnings.
Ceftaroline Fosamil (Teflaro) - A New IV Cephalosporin
The Medical Letter on Drugs and Therapeutics • January 24, 2011; (Issue 1356)
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by...
The FDA has approved ceftaroline fosamil (Teflaro –
Forest), an intravenous (IV) cephalosporin, for treatment
of acute bacterial skin and skin structure infections,
including those caused by methicillin-resistant
Staphylococcus aureus (MRSA), and for treatment of
community-acquired bacterial pneumonia in adults. It
is the first beta-lactam antibiotic approved for treatment
of MRSA.
Aztreonam for Inhalation Solution (Cayston) for Cystic Fibrosis
The Medical Letter on Drugs and Therapeutics • August 9, 2010; (Issue 1344)
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa....
The antibiotic aztreonam is now available as an inhalation solution (Cayston – Gilead) to improve respiratory symptoms in cystic fibrosis (CF) patients ≥7 years old colonized with Pseudomonas aeruginosa. It is the second inhaled antibiotic to be FDA-approved for this indication in CF patients; the aminoglycoside tobramycin (Tobi) was the first. Inhaled antibiotics offer the advantage of high airway concentrations while minimizing systemic side effects.
Drugs for Bacterial Infections
The Medical Letter on Drugs and Therapeutics • June 1, 2010; (Issue 94)
The text below reviews some common bacterial infections and their treatment. The recommendations made
here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter...
The text below reviews some common bacterial infections and their treatment. The recommendations made
here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Doripenem (Doribax) - A New Parenteral Carbapenem
The Medical Letter on Drugs and Therapeutics • January 28, 2008; (Issue 1278)
Doripenem (Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of...
Doripenem (Doribax - Ortho-McNeil Janssen), an intravenous (IV) carbapenem antibiotic with a spectrum of activity similar to that of imipenem and meropenem, has been approved by the FDA for treatment of complicated intra-abdominal and urinary tract infections. Use of doripenem for treatment of nosocomial pneumonia, including ventilator-associated pneumonia, is still under FDA review.
Choice of Antibacterial Drugs
The Medical Letter on Drugs and Therapeutics • May 1, 2007; (Issue 57)
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric...
Information about empirical treatment of bacterial infections, emerging trends in antimicrobial resistance, new drugs and new data about older drugs continue to become available. Usual pathogens and empiric treatment for some common types of infections are summarized in the text and a table listing the drugs of choice and alternatives for each pathogen begins on page 40. The recommendations made here are based on the results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants.
Tigecycline (Tygacil)
The Medical Letter on Drugs and Therapeutics • September 12, 2005; (Issue 1217)
Tigecycline (Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure...
Tigecycline (Tygacil - Wyeth), a derivative of minocycline, is a new intravenous (IV) antibiotic approved for treatment of complicated intra-abdominal and skin and skin-structure infections.
Choice of Antibacterial Drugs
The Medical Letter on Drugs and Therapeutics • March 1, 2004; (Issue 19)
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the...
New drugs for bacterial infections and new information about older drugs continue to become available. Empirical treatment of some common bacterial infections is discussed in this article. A table listing the drugs of choice and alternatives for each pathogen begins on page 18. These recommendations are based on results of susceptibility studies, clinical trials and the opinions of Medical Letter consultants. Local resistance patterns should be taken into account. Trade names are listed on page 24.
Drugs for Pneumonia
The Medical Letter on Drugs and Therapeutics • September 1, 2003; (Issue 13)
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid...
The choice of drugs for treatment of pneumonia depends on the most likely pathogens causing the infection and local antimicrobial resistance patterns. Factors such as severity of illness, presence of co-morbid conditions and whether the infection is community or hospital-acquired also need to be considered.
The Choice of Antibacterial Drugs
The Medical Letter on Drugs and Therapeutics • August 20, 2001; (Issue 1111)
New drugs for treatment of bacterial infections and new information about older drugs continue to become available. Empirical treatment of some infections is discussed and a table listing the drugs of choice...
New drugs for treatment of bacterial infections and new information about older drugs continue to become available. Empirical treatment of some infections is discussed and a table listing the drugs of choice and alternatives for each pathogen are contained in this article. These recommendations are based on results of susceptibility studies, clinical trials and opinions of Medical Letter consultants. Local resistance patterns should be taken into account.
The Choice of Antibacterial Drugs
The Medical Letter on Drugs and Therapeutics • October 22, 1999; (Issue 1064)
Since The Medical Letter last reviewed the choice of drugs for treatment of bacterial infections, a few new drugs and some new information about older drugs have become...
Since The Medical Letter last reviewed the choice of drugs for treatment of bacterial infections, a few new drugs and some new information about older drugs have become available.